CUTIA-B (02487.HK) +0.030 (+0.690%) announced that its CU-30101 (topical lidocaine and tetracaine cream) has obtained marketing approval from the National Medical Products Administration of the People's Republic of China.CU-30101 is a topical lidocaine and tetracaine combination cream for epidermal anesthesia procedures. Owing to the unique pharmacokinetic properties of its ingredients, the combination formulation of lidocaine and tetracaine in CU-30101 delivers rapid and sustained anesthetic effects. Lidocaine diffuses faster and across a broader area than tetracaine, while tetracaine, a long-acting amino ester local anesthetic, is more lipophilic than lidocaine and can concentrate in the stratum corneum. In addition, the topical cream formulation limits systemic absorption of the anesthetic components, thereby offering a favorable safety profile. (ec/w)(HK stocks quote is delayed for at least 15 mins.)
AASTOCKS Financial News